Skip to content
Friedreich's Ataxia News logo
  • Forums
  • About FA
    What is FA?
    Causes
    Symptoms
    • Cardiomyopathy
    Diagnosis
    Treatments
    • Approved treatment: Skyclarys
    • Experimental Treatments
    • Non-drug Treatments
  • News
  • Columns
    Defining Yourself — Jean Walsh
    My Darling Disability
    — Kendall Harvey
    Little Victories — Matthew Lafleur
    Recalibrating – Elizabeth Hamilton
    Archived Columns
    • No Good Excuse — Sean Baumstark
    • Hope from Home — Katie Griffith
    • An Unexpected Journey — David Riley
    • Practical Guide to Life with FA — Christina Cordaro
  • FA education
    Videos: Start strong, stay steady
    My FA diagnosis story
    Growing up with FA
    Talking to your child about FA
    Assistive equipment, aids, and adaptations
    Guidance for parents of children with FA
    FA treatment options
    Exercise and physiotherapy
    Living with FA
    FA support and resources
    FA and mental health
    Essential travel tips
    Speech therapy
    AAC devices
    Occupational therapy
    FA and diet
    Late-onset FA
    Aging with FA
  • Find a physician
  • For professionals
  • Advocacy partners
  • What can we help you find today?

    • Forums

Screening Friedreich's ataxia patients for Skyclarys treatment

George Wilmot, MD, PhD, shares the demographics, such as age and disease stage, that make for ideal candidates for treatment with Skyclarys.

About George Wilmot, MD, PhD

George Wilmot, MD, PhD, is a board-certified neurologist affiliated with a few hospitals, including Emory University Hospital. He also serves as an associate professor at Emory University School of Medicine’s Department of Neurology and adjunct associate professor at the the school’s Department of Pediatrics. He is an ataxia clinical researcher and he started the Cooperative Ataxia Registry.

 

Transcript

Well, Skyclarys is FDA-approved for 16 and over. And, so that’s the appropriate age.

The drug has been shown to perhaps reduce the progression rate to some degree. And in doing that, I think that it can be an important thing for providers to prescribe for the right patients.

I think most Friedrich’s patients that fit in the right age group that don’t have contraindications — like bad liver failure, bad heart failure — those really weren’t studied in the studies that led to its approval; they were excluded. So most other patients, I think, have the potential for benefit.

I’ve had patients that have declined taking it because they are at such a late stage that it really didn’t make sense for them to prolong their disease. For that reason, you know, the very, very late-stage Friedrich’s is a question of whether they should take it or not.

But I think the majority of patients that are of appropriate age are possible candidates and really should be considered for Skyclarys therapy.

Our FA medical advisor

Dr. David LynchDavid Lynch, MD, PhD, is the director of the Friedreich’s Ataxia Program at Children’s Hospital of Philadelphia.

Meet the expert

Newsletter driver

Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

This field is for validation purposes and should be left unchanged.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.